Australia contributes to the Global Fund to Fight AIDS, Tuberculosis and Malaria, an international financing partnership that supports large scale prevention, treatment and care programs and strengthens health systems in developing countries; and Gavi the Vaccine Alliance to support immunisation and health systems, and introduce new vaccines in developing countries.
To complement and support our country programs and global health funds investments, DFAT also supports global initiatives to improve development co-operation on priority health issues, and to increase the effectiveness of our health development program. Information on some of these key activities can be found below.
World Health Organization (WHO)
$12.4 million, 2015-16 (Core contribution)
The World Health Organization (WHO) is the directing and coordinating authority on international health within the United Nations (UN) system. WHO also leads responses to global and regional health threats and is the lead for the UN Inter-Agency Standing Committee’s Global Health Cluster in humanitarian emergencies. Australia provides WHO with annual core voluntary contributions in a flexible and predictable manner to support the WHO’s General Programme of Work. Australian Government funding contributes to:
- strengthening health systems especially in the Asia Pacific region
- identifying and addressing emerging regional health issues.
United Nations Population Fund (UNFPA)
$9.24 million, 2015-16 (Core contribution)
The United Nations Population Fund (UNFPA) is a key player in supporting global achievement of the health, education and gender equality Sustainable Development Goals. It assists countries in collecting, analysing and disseminating population data, and supports developing policies and programs on gender and maternal health, particularly in reproductive health, including family planning, safe motherhood, HIV/AIDS prevention, gender-based violence and promoting gender equality. UNFPA also provides technical guidance, training and support to its partners in the field.
Australia provides UNFPA with annual core voluntary contributions in a flexible and predictable manner to support the implementation of UNFPA’s Strategic Plan.
The Joint United Nations Programme on HIV/AIDS (UNAIDS)
$4.5 million, 2015-16 (Core contribution)
The Joint United Nations Programme on HIV/AIDS (UNAIDS) is the primary global multilateral agency responding to HIV/AIDS. Its mandate is to provide international coordination, leadership, strategic guidance and advocacy to mobilise global resources for the HIV response.
Australia provides UNAIDS with annual core funding, to support implementation of the UNAIDS Strategy, with a focus on the Asia-Pacific region.
Asia Pacific Malaria Elimination Network (APMEN)
$7.65 million, 2009-2016
The Asia Pacific Malaria Elimination Network (APMEN) is a network of partner governments, donor organisations and public health, academic, and private sector institutions in Asia and the Pacific. The aim of APMEN is to develop and sustain a network of partner countries and institutions to work collaboratively to address the challenges of malaria elimination, with particular focus on the unique challenges for the region such as Plasmodium vivax. APMEN seeks to achieve this through activities relating to leadership, advocacy, capacity building, knowledge exchange, and building the evidence base.
Health research for development
$30 million per year, beginning 2014-2015
On 18 June 2014, when launching the new aid policy, the Minister for Foreign Affairs, the Hon Julie Bishop MP, announced that the Australian aid program will invest $30 million per year in health and medical research. This package will support operational research through bilateral country programs, innovation for health and Product Development Partnerships (PDPs). In March 2015, the Minister for Foreign Affairs announced a contribution of $30 million (over three years) to PDPs to TB Alliance, Medicines for Malaria Venture (MMV), and Foundation for Innovative New Diagnostics (FIND) to bring to market diagnostics and medicines for TB and malaria including a new all-oral regimen which treats drug-sensitive and multi-drug resistant TB.